Research graph
References from Re-evaluating aglatimagene in localised prostate cancer – Authors' reply. Local targets link to admitted publications; unresolved targets remain external evidence.
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
10.1016/s1470-2045(26)00071-9 · 2026 · External reference
Long-term biopsy outcomes in prostate cancer patients treated with external beam radiotherapy: a systematic review and meta-analysis
10.1038/s41391-021-00323-6 · 2021 · External reference
The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome
10.1016/j.ijrobp.2006.09.027 · 2007 · External reference
Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial
10.1002/cncr.24020 · 2009 · External reference
Assessment of the rate of adherence to international guidelines for androgen deprivation therapy with external-beam radiation therapy: a population-based study
10.1016/j.eururo.2016.02.057 · 2016 · External reference
10.1097/01.ju.0001192572.07890.f8.01
10.1097/01.ju.0001192572.07890.f8.01 · 2026 · External reference
